Vaxcyte Stock Today

PCVX Stock  USD 114.42  2.82  2.53%   

Performance

8 of 100

 
Weak
 
Strong
OK

Odds Of Distress

Less than 25

 
High
 
Low
Low
Vaxcyte is trading at 114.42 as of the 11th of October 2024; that is 2.53 percent increase since the beginning of the trading day. The stock's open price was 111.6. Vaxcyte has about a 25 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Vaxcyte are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2022 and ending today, the 11th of October 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
12th of June 2020
Category
Healthcare
Classification
Health Care
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. Vaxcyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 123.78 M outstanding shares of which 9.65 M shares are at this time shorted by private and institutional investors with about 5.92 trading days to cover. More on Vaxcyte

Moving together with Vaxcyte Stock

  0.82DMAC DiaMedica TherapeuticsPairCorr

Moving against Vaxcyte Stock

  0.76VALN Valneva SE ADRPairCorr
  0.62VCEL Vericel Corp OrdPairCorr
  0.61DRMA Dermata TherapeuticsPairCorr
  0.47ME 23Andme HoldingPairCorr
  0.47VCNX VaccinexPairCorr
  0.45VANI Vivani MedicalPairCorr

Vaxcyte Stock Highlights

ESG Sustainability
Environmental
Governance
Social
President CFOAndrew MBA
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities152.6 M145.3 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total43.8 M22.1 M
Way Up
Slightly volatile
Total Assets1.5 B1.4 B
Sufficiently Up
Slightly volatile
Total Current Assets1.2 B1.1 B
Sufficiently Up
Slightly volatile
Debt Levels
Vaxcyte can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vaxcyte's financial leverage. It provides some insight into what part of Vaxcyte's total assets is financed by creditors.
Liquidity
Vaxcyte currently holds 29.22 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Vaxcyte has a current ratio of 11.7, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Vaxcyte's use of debt, we should always consider it together with its cash and equity.

Other Non Cash Items

(22.37 Million)
Vaxcyte (PCVX) is traded on NASDAQ Exchange in USA. It is located in 825 Industrial Road, San Carlos, CA, United States, 94070 and employs 254 people. Vaxcyte is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 13.81 B. Vaxcyte conducts business under Biotechnology sector and is part of Health Care industry. The entity has 123.78 M outstanding shares of which 9.65 M shares are at this time shorted by private and institutional investors with about 5.92 trading days to cover. Vaxcyte currently holds about 354.5 M in cash with (296.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.98.
Check Vaxcyte Probability Of Bankruptcy
Ownership Allocation
The majority of Vaxcyte outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vaxcyte to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vaxcyte. Please pay attention to any change in the institutional holdings of Vaxcyte as this could imply that something significant has changed or is about to change at the company.
Check Vaxcyte Ownership Details

Vaxcyte Stock Institutional Holders

InstituionRecorded OnShares
Geode Capital Management, Llc2024-06-30
2.4 M
Darwin Global Management, Ltd.2024-06-30
2.1 M
Driehaus Capital Management Llc2024-06-30
1.9 M
Westfield Capital Management Company, Lp2024-06-30
1.9 M
Perceptive Advisors Llc2024-06-30
1.9 M
Alliancebernstein L.p.2024-06-30
1.7 M
Jennison Associates Llc2024-06-30
1.4 M
Fred Alger Management, Llc2024-06-30
1.3 M
Commodore Capital Lp2024-06-30
1.3 M
Fmr Inc2024-06-30
16.2 M
Blackrock Inc2024-06-30
9.9 M
View Vaxcyte Diagnostics

Vaxcyte Historical Income Statement

At this time, Vaxcyte's Cost Of Revenue is fairly stable compared to the past year. View More Fundamentals

Vaxcyte Stock Against Markets

Vaxcyte Corporate Management

Mikhail JDGeneral VPProfile
Karen AldereteEx HRProfile
Whitney JonesChief OfficerProfile
Ashish MBACoFounder OfficerProfile
Jeff FairmanCoFounder ResearchProfile
Grant MBACEO CoFounderProfile

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.